



Media Contact:

Carol Berry

Chief Business Officer, SVP

Caprion, Inc.

[cberry@caprion.com](mailto:cberry@caprion.com)

514.360.3600

## **Caprion Presented Case Studies Demonstrating how Multiparametric Flow Cytometry is Applied during Pre-clinical and Clinical Development**

**Montreal, Canada - August 14, 2014** - Caprion's immune monitoring business unit, ImmuneCarta®, presented case studies demonstrating how immune monitoring and associated profiling tools are routinely used during pre-clinical and clinical development programs. The case studies were presented at the *Target Discovery for T Cell Therapy Conference* track during the Immunotherapies and Vaccine Summit (ImVacS), which concluded last week in Boston, MA.

Through ImmuneCarta's assays, it was shown that polyfunctional cancer-specific CD8 T cells were successfully mobilized against the tumor in ovarian cancer patients. Successful T cell induction was achieved by the DPX-Survivac vaccine, developed by ImmunoVaccine. The study also showed how the phenotype of cells dramatically differs with age and that the assay could potentially be used to identify patients who are likely to respond to the vaccine.

"The combination of multiparametric flow cytometry and immune monitoring in a GLP/GCLP-compliant environment is capable of identifying correlates of immune protection, effectively accelerating the development of novel therapies such as checkpoint and kinase inhibitors, adoptive T-cell therapies, and vaccines," said Yoav Peretz, Ph.D., Scientific Director for ImmuneCarta.

Carol Berry, Chief Business Officer and Senior Vice President of Caprion, additionally commented, "We have been delighted with the strong interest from the conference attendees regarding our flow-based assays and immune monitoring services to assist in a growing number of immunotherapy programs."

### **About Caprion**

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion's proteomics business unit, ProteoCarta®, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion

also leverages ProteoCarta® to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit [www.caprion.com](http://www.caprion.com).